-
FDA approves Alecensa as leading-edge adjuvant therapy for ALK-positive lung cancer
02 May 2024 19:18 GMT
… ALK-positive non-small cell lung cancer (NSCLC) patients. The … 2015, following Pfizer’s Xalkori (crizotinib) for metastatic ALK … given that ALK-positive lung cancer patients typically receive their … diagnosed with early-stage lung cancer to ensure they receive …
-
Roche Drug Scores Label Expansion for Earlier Use in Lung Cancer
19 Apr 2024 18:55 GMT
… cancer drug that treats lung cancer with a certain genetic … treatment for non-small cell lung cancer (NSCLC). The latest … England Journal of Medicine.
Lung cancer often metastasizes to the … of ALK inhibitors includes Xalkori and Lorbrena from Pfizer, …
-
Roche wins FDA OK for targeted drug in early lung cancer
19 Apr 2024 14:40 GMT
… each year from lung cancer, and 80% to 85% of lung tumors are of … positive. Drugs aimed at another lung cancer target, TROP2, are in … for the estimated 5% of lung cancer patients with ALK mutations. … disease, as are Pfizer’s Xalkori and Takeda’s Alunbrig. But …
-
ALK-Positive Lung Cancer in Focus
05 Mar 2024 00:04 GMT
… 4 cancer diagnosis, lung cancer specifically, without having … including] lung cancer.”
“When we talk about ALK-positive lung cancer, we … with ALK-positive lung cancer, with researchers writing … “durable benefit ... over [Xalkori] in patients with treatment- …
-
Repotrectinib Expands Treatment Options for Lung Cancers with ROS1 Fusions
16 Feb 2024 16:45 GMT
… drug, such as crizotinib (Xalkori) or entrectinib (Rozlytrek), … with ROS1 fusion–positive lung cancers, including those who … drug resistance
Some lung tumors develop genetic mutations in … treatment options for advanced lung cancers with ROS1 fusions
ROS1 …
-
FDA approves new Bristol Myers drug for lung cancer
16 Nov 2023 21:00 GMT
… Myers Squibb’s new lung cancer medication Augtyro, which the … cell lung cancer have this alteration, and Pfizer’s Xalkori and … Opdivo transformed the treatment of lung cancer. But for patients with … in non-small cell lung cancer patients with the ROS1 …
-
Bristol Myers' $4.1B Turning Point buy yields FDA approval for lung cancer drug Augtyro
16 Nov 2023 16:48 GMT
… Squibb is entering a niche lung cancer market.
The FDA has … to treat non-small cell lung cancer (NSCLC) patients whose tumors … FDA approvals. Pfizer’s Xalkori became the first TKI greenlighted … .
Before Augtyro’s approval, Xalkori has been the treatment of …
-
STAT+: Bristol wins U.S. approval for lung cancer drug targeting rare genetic mutation
16 Nov 2023 12:23 GMT
… people with non-small cell lung cancer that contains a rare genetic … ’s Xalkori and Roche’s Rozyltrek — that also treat Ros1-altered lung cancer … in about 2% of all lung cancer cases. But Augtryo was designed …
-
Bristol Myers Squibb scores FDA approval for lung cancer drug from Turning Point buyout
16 Nov 2023 12:14 GMT
… cell lung cancer. It will be a new rival to Pfizer’s Xalkori …
-
ESMO: Roche's Alecensa staves off lung cancer recurrence en route to postsurgery expansion
21 Oct 2023 17:28 GMT
… trial win for its targeted lung cancer therapy Alecensa that should enable … , ALK-positive non-small cell lung cancer (NSCLC), according to phase 3 … 29% compared with Pfizer’s Xalkori after a long-term follow …